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The caprine arthritis encephalitis virus (CAEV) Vif protein is necessary for a productive infection of susceptible goat cells.
The vif gene is conserved among all primate and most nonprimate lentiviruses. However, previous reports demonstrated that,
in their respective host cells, primate Vif deleted lentiviruses could not be complemented by nonprimate Vif proteins,
suggesting that species-specific restrictions between Vif and the virus-producing cells may modulate the Vif function on viral
infectivity. Here we bring further support to this hypothesis since we show that CAEV Vif, when expressed in goat cells, is
able to increase the infectivity of Vif deleted human immunodeficiency type-1 virus and of murine leukemia virus. Moreover,
we demonstrate in vitro interactions between different Vif proteins and NC domains of heterologous Gag precursors,
supporting the notion that species specificity of lentiviral infection is not due to molecular interactions between Vif and viral
components. © 2002 Elsevier Science
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Caprine arthritis encephalitis virus (CAEV) is a retro-
virus which infects goats worldwide and induces pro-
gressive degenerative inflammatory diseases in infected
animals. The CAEV genome is related to other lentivi-
ruses and contains a vif gene in addition to the structural
gag, pol, env, and regulatory tat, rev genes (Saltarelli et
al., 1990). The CAEV vif gene is required in vivo to estab-
lish persistent infection and pathogenesis (Harmache et
al., 1996). In vitro studies on CAEV Vif deletion mutants
showed that this protein is required to allow efficient viral
production by acting during the late stages of virus rep-
lication (Harmache et al., 1995). We recently demon-
strated specific in vitro interactions between CAEV Vif
and the nucleocapsid (NC) domain of the Gag precursor
protein (Pr55gag), dependent on the presence of the two
NC Zn finger motifs (Seroude et al., 2001). However, this
interaction, per se, did not correlate with the Vif function
on virion infectivity, in contrast to previous results ob-
tained with the Vif and Gag proteins of human immuno-
deficiency type-1 virus (HIV-1) (Bouyac et al., 1997). The
essential role of Vif in viral replication and infectivity is
now established for most of the primate and nonprimate
lentiviruses. Some studies, defining complementation
patterns of Vif deleted (Vif2) HIV-1 by only primate len-
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156tiviral Vif proteins, suggested that the Vif function might
be governed by interactions with species-specific host
cell factor(s) (Madani and Kabat, 2000; Simon et al., 1995,
1998). Whether these restrictions occur regardless of
Vif/virus interactions leads to contradictory results on the
role of HIV-1 Vif, expressed by human cells, on the
modulation of infectivity of the distantly related murine
leukemia virus (MLV) (Madani and Kabat, 2000; Simon et
al., 1998). These reports raised the question of the virus-
specific effects of the Vif protein. If such interactions are
also involved in Vif function, they should take place
between Vif and a conserved sequence or structure of
another viral component. To gain new insights into the
relevance of each of these two kinds of interaction, i.e.,
virus-specific and host-species-specific in Vif function,
we extended our study of Vif/Gag interactions to proteins
from several different lentiviruses and retroviruses, and
we analyzed the effect of the species-specific cellular
environment on CAEV Vif function.
RESULTS AND DISCUSSION
The NC domain of retroviral Gag precursors mediates
nucleic acid binding through their Zn finger motifs (Cof-
fin, 1996). Vif proteins are highly basic and recent reports
described HIV-1 Vif protein as an RNA binding protein
(Dettenhofer et al., 2000; Zhang et al., 2000). These re-
sults would suggest that Vif proteins might bind to Gag
precursors via the nucleic acid–NC complexes. To ad-
dress the issue of the conservation of Vif/Gag interac-
tions among different lentiviruses, the NC domain of the
gag genes of human type-1 and type-2, feline and simian
immunodeficiency viruses (HIV-1 NDK (Spire et al., 1989),
HIV-2 ROD (Guyader et al., 1987), FIV Pet (Talbott et al.,
e amo
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Desrosiers, 1990, respectively) were cloned in frame with
the GST gene to produce the corresponding GST–NC
fusion proteins. The analysis was also performed with
GST–NCs from the lentivirus equine infectious anemia
virus (EIAV19.2, Payne et al., 1994) or retroviruses, such
as the amphotropic murine leukemia virus (Mo(4070A),
Ott et al., 1992) and Jaagsiekte sheep retrovirus (JSRV,
York et al., 1992), that lack vif genes. Equal amounts (2–5
mg) of GST or GST–NC proteins were bound to glutathi-
one beads and then incubated with in vitro translated
35S-methionine-labeled CAEV, HIV-1, HIV-2, or FIV Vif pro-
teins. Binding assays were performed as previously de-
scribed (Seroude et al., 2001) in the presence of NaCl
concentrations ranging from 0.1 to 1 M. As shown in Fig.
1A, a specific Vif/GST–NC interaction was still observed
for HIV-2 and FIV proteins in the presence of 0.4 and 0.5
M NaCl, respectively. Interestingly, as shown in Fig. 1B,
CAEV Vif protein bound specifically to HIV-2 GST–NC
protein and to retroviral MLV GST–NC protein but not to
GST. These interactions were still detected in the pres-
ence of 0.4 M NaCl. Conversely, 35S-labeled HIV-1 or
HIV-2 Vif proteins bound the CAEV GST–NC protein in
FIG. 1. In vitro interactions between Vif and NC domains. (A) Hom
proteins from HIV-2 (left) and FIV (right) with their respective NC dom
GST-NC HIV-2 (upper left) and GST-NC MLV (upper right) or between HI
was used in equal amounts as GST–NC as a specificity control (gst). Th
(input), and the binding reaction was performed in the presence of incthe presence of 0.3 and 0.5 M NaCl, respectively. As
summarized in Table 1, the different lentiviral Vif proteinstested bound specifically to heterologous lentiviral or
retroviral GST–NC proteins. These interactions were
confirmed with GST–Gag proteins (data not shown).
s interactions between in vitro translated 35S-methionine-labeled Vif
sed to GST. (B) Heterologous interactions between CAEV 35S-Vif with
er left) and HIV-2 (lower right) 35S-Vif proteins with GST–NC CAEV. GST
unt of radioactive material used in each assay is shown in the left lane
g NaCl concentrations.
TABLE 1
Homologous and Heterologous Interactions between Lentiviral Vif
Proteins and Retroviral Gag Precursor or NC Domain Using the in




CAEV HIV-1 HIV-2 FIV
CAEV 11 11 11 11
HIV-1 11 11 11 111
HIV-2 11 11 11 11
SIV 11 11 11 11
FIV NT NT NT 11
EIAV 111 11 111 11
MoMLV 11 11 11 111
JSRV 11 1 11 1
Note. In vitro translated and 35S-metabolically labeled Vif proteins
were allowed to react with the different GST–NC or GST–Gag fusion
proteins bound to glutathione beads in the presence of various con-
centrations of NaCl, as in Fig. 1. Vif/Gag interaction is still detectable atologou
ains fu
V-1 (lowa concentration of 0.15 M NaCl (1); between 0.15 and 0.5 M NaCl (11);
and between 0.5 and 1 M NaCl (111). NT, not tested.
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bind another viral protein such as integrase or the Dro-
sophila zinc finger containing TeaShirt protein (Seroude
et al., 2001), it might be concluded that the Vif/NC inter-
actions are the result of sequence-specific recognition.
As other specificity controls, no binding was observed
between each of the GST–NC or GST–Gag fusion pro-
teins and in vitro translated 35S-labeled luciferase (data
not shown).
These results demonstrated the ability of Vif proteins
to specifically bind in vitro to homologous or heterolo-
gous NC domains or Gag precursors. Since interactions
were detected with Gag proteins from lentiviruses that
express a Vif protein, as well as from EIAV or retroviruses
such as MLV and JSRV that do not, they might be the
result of common biochemical characteristics shared by
each of these proteins. We recently showed that a CAEV
Vif mutant, still able to interact with CAEV GST–NC, was
severely impaired for efficient replication, implying that
the essential function of Vif for infectivity might be un-
coupled from its property to bind to the structural Gag
precursor (Seroude et al., 2001). Moreover, Vif of maedi-
visna virus, a sheep lentivirus closely related to CAEV,
was not found to be associated to the released progeny
virion (Audoly et al., 1992), whereas Vif of HIV-1 was
either undetectable (Dettenhofer and Yu, 1999) or asso-
ciated to immature particles (Sova et al., 2001). All of
these results lead to the hypothesis that Vif/Gag interac-
tions might be transient during the replication cycle,
although their biological significance remains to be elu-
cidated. These interactions might account for broad viral
specificities of the Vif proteins, which might be counter-
acted by cell species restriction to determine the virus
host range.
We next studied the ability of the CAEV Vif protein,
when expressed in primary goat synovial membrane
(GSM) cells, to complement Vif defective HIV-1. GSM
cells were transiently cotransfected with HIV-1 NDK wild-
type (wt) or Vif deleted proviral DNA (Blanc et al., 1993),
together with the CAEV Vif expression plasmid pRCVif
(Harmache et al., 1995) or the pRC vector as a control.
Viral supernatants were normalized according to reverse
transcriptase activity (RT). Supernatants with equal
amounts of RT activity were used to infect C8166-CCR5/
LTR HIV-CAT cells (Fouchier et al., 1997). Quantitation of
HIV-1 particle infectivity was performed either by mea-
suring the induction of chloramphenicol-acetyl trans-
ferase (CAT) activity at 24 h postinfection (Fig. 2A) or by
end-point virus titration on the same target cells at day 7
postinfection (Fig. 2B). Infectious HIV-1 Vif-particles were
released in the transfection supernatant of GSM cells.
Interestingly, they were more infectious when produced
in the presence of CAEV Vif (14.9-fold activation of CAT
production and 103 TCID50/ml) than in its absence (6.7-
2fold activation and 10 TCID50/ml). However, the expres-
sion of CAEV Vif in the producing cells has little or noeffect on the infectivity of HIV-1 wt (5.3-fold activation and
about 0.5 102 TCID50/ml). This highly reproducible obser-
vation might be interpreted as the result of a better
affinity interaction between a given Vif protein and its
respective viral components. In the absence of the ho-
mologous Vif, any other Vif protein should complement
Vif deleted proviruses, provided that Vif is expressed
within a relevant cellular context. Our study strongly
suggests that, although heterologous interactions might
take place between Vif and Gag proteins, the effect of Vif
on viral infectivity would only be observed in cell species
related to the natural viral host. In this way these results
might explain the absence of complementation of HIV-1
Vif2 by maedi-visna virus Vif in human cells (Simon et
al., 1995). Since specific interactions were shown be-
tween CAEV Vif and MLV GST–NC, we then examined
whether this might result in an increase in the infectivity
of MLV produced by caprine cells expressing CAEV Vif.
GSM cells were cotransfected with the proviral DNA
from the amphotropic Mo(4070A) MLV (Ott et al., 1992)
and pRC or pRCVif. Culture supernatants were harvested
and normalized as described above. Equal amounts of
RT activity were used to infect NIH 3T3 target cells, and
viral replication was measured as the transcription level
of the MLV spliced env mRNA using a semi-quantitative
FIG. 2. CAEV Vif increases the infectivity of HIV-1 Vif2 in caprine
cells. GSM cells were transiently cotransfected with the indicated
DNAs, and the corresponding culture supernatants were harvested at
48–72 h posttransfection and normalized as to their reverse transcrip-
tase activity. Results are the average of three independent experiments.
A. Extent of infectivity measured as the induction of CAT expression in
C8166-CCR5/HIV-CAT cells. Results are shown as fold activation of CAT
production following correction for background CAT activity in mock-
infected cells. B. Viral infectivity as measured by tissue culture infec-
tious dose (TCID50/ml) on C8166 cells at day 7 postinfection. The
infectious titer was determined as the last viral supernatant dilution
inducing syncitia in half of the culture wells.RT-PCR assay. As shown in Fig. 3, equal amounts of
GAPDH RNA were amplified in each of the four extracts.
ndepen
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crease in viral RNA transcription in NIH 3T3 cells in-
fected with MLV particles produced by GSM cells ex-
pressing CAEV Vif, compared to RNA extracted from
cells infected with MLV produced without CAEV Vif.
These results are in agreement with those previously
published by Simon et al. (1998) reporting a similar effect
of HIV-1 Vif expressed by nonpermissive human cells on
MLV replication. The presented data show that CAEV Vif
slightly increases the infectivity of retroviruses when
expressed in its species-specific cellular environment.
The experimental system used in this study based on
transient cotransfection experiments, without any selec-
tion of the transfected cells, might account for the low
level effect obtained, which was reproducible in two
different viral environments (HIV Vif2 and MLV).
These results bring new support to the notion that
interactions with species-specific cellular factor(s) are
critical for Vif function since Vif of nonprimate lentivi-
ruses that were described as inefficient to complement
HIV-1 Vif2 in human cells (Simon et al., 1995) proved to
be competent when expressed in their relevant target
cells. All together, these results strongly argue for a
conserved mechanism underlying Vif-mediated increase
in the infectivity of retroviruses. Our study points out
interactions between Vif and the NC domain of Gag
precursors as a possible mechanism that might explain
the effect of Vif on several different enveloped viruses.
Our current hypothesis is that Vif confers infectivity on a
wide range of retroviruses, by means of viral interactions,
but its function is restricted to a limited number of cell
species, closely related to the natural animal viral host,
by means of interactions with species-specific cellular
factor(s). The demonstration of Vif/Gag interactions in
different cellular environments, relevant or not for the Vif
function, should bring a strong argument to this hypoth-
FIG. 3. Enhancement of MLV replication in caprine cells by CAEV Vif
used to infect NIH 3T3 cells. Total RNA was extracted from the infected
transcription level of the MLV env gene (559 bp, right) or of the house
RNA were used in the RT-PCR reaction, starting with 100 ng, and the
32P-labeled oligonucleotide probes. Representative results from three i
infected NIH 3T3 cells (100 ng).esis. Since we and others (Simon et al., 1995) reported
the effect of Vif on viruses that lack vif genes such asMLV, it should be interesting to study whether Vif expres-
sion can modulate the infectivity of EIAV, the only lenti-
virus without Vif protein. If the results obtained on MLV
infectivity are extended to EIAV, they might provide in-
sight on the adaptation of this virus to grow in the
absence of Vif. If the Vif protein, as suggested by its
name, is a true viral infectivity factor responsible for
increased pathogenicity in infected animals, then one of
the major differences between EIAV and other lentiviral
infections, that many horses efficiently suppress clinical
disease following the onset of clinical signs, might be
assumed as a consequence of the lack of Vif in the EIAV
genome. The dissection of the molecular mechanism(s)
of viral and/or cellular interactions required for Vif func-
tion would allow a better understanding of the regulation
of lentiviruses replication and pathogenesis.
MATERIALS AND METHODS
Construction of pGEX plasmids
The pGEX-5X-2 vector (Pharmacia) was used to obtain
the GST–NC fusion proteins from HIV-2, FIV, SIVmac,
EIAV, MLV, and JSRV. The different NC coding sequences
were obtained by PCR using the following primers: NC
HIV-2 forward: positions 1567–1586/reverse: positions
2119–2100, according to Guyader et al. (1987); NC FIV
forward: positions 1713–1730/reverse: positions 2115–
2104, according to Talbott et al. (1989); NC SIVmac for-
ward: positions 2450–2464/reverse: positions 2841–2823
according to Regier and Desrosiers (1990); NC EIAV for-
ward: positions 1581–1597/reverse positions 1985–1967 ac-
cording to Payne et al. (1994); NC MoMLV forward: posi-
tions 1791–1809/reverse 1962–1941 according to Petropou-
los (1997); NC JSRV forward: 1570–1590/reverse: 2101–2083
according to York et al. (1992). The amplified NC fragments
were cloned at the EcoRI or BamHI site of the pGEX-5X-2
. Transfection supernatants were produced as described for Fig. 2 and
at 72 h postinfection and analyzed by semi-quantitative RT-PCR for the
g GAPDH gene as a control (382 bp, left). Serial threefold dilutions of
d products were analyzed by Southern blot using respective internal
dent experiments are shown. 1, RNA extracted from control MoMLV-protein
cells
keepin
amplifievector, in frame with the glutathione S-transferase gene.
The pGEX-NC CAEV was previously described (Seroude et
160 SEROUDE ET AL.al. 2001) and the pGEX-NC HIV-1 was given by Dr. B. Spire
(Bouyac et al., 1997). Expression and purification of GST
fusion proteins as well as binding assays were as previ-
ously described (Seroude et al., 2001).
In vitro protein translation
Vif protein synthesis was performed with the TnT T3
wheat germ extract systems (Promega) following the
manufacturer’s recommendations. The vif genes were
amplified from the different plasmids using the following
primer pairs: vif HIV-2 forward: positions 4869–4885/
reverse: 5516–5498 according to Guyader et al. (1987); vif
FIV forward: 5376–5392/reverse: 5990–5974 according to
Talbott et al. (1989). Each forward primer contained the
T3 sequence 59 from the vif specific sequence. The PCR
products were cloned into the PCR II vector (TA cloning
kit, InVitrogen) and then used to allow proteins transcrip-
tion/translation in the presence of (35S)-methionine
(.1000 Ci/mmol; Amersham). The plasmid allowing ex-
pression of CAEV Vif was previously described (Seroude
et al., 2001), as well as the one for HIV-1 Vif expression
(Bouyac et al., 1997).
Cell transfection
Explanted goat primary synovial membrane cells were
maintained in MEM medium supplemented with 10%
fetal calf serum, 100 IU/ml penicillin, 100 mg/ml strepto-
mycin, and 2 mM glutamine. For transfection experi-
ments, cells were seeded at 2 3 105 cells/cm2 the day
before. They were transfected using the Lipofectamine
reagent (Life Technologies) with 5 mg of total DNA com-
posed of equal amounts of the pRC vector or pRC-Vif
CAEV plasmid (Harmache et al., 1995) and the proviral
DNAs coding for HIV-1 pNDK wild-type or vif deleted
(Blanc et al., 1993) or the amphotropic MLV pMo(4070A)
(Ott et al., 1992). After 2 h at 37°C, the medium was
replaced and the cell culture supernatants were har-
vested at 72 h posttransfection, cleared by low-speed
centrifugation, and normalized according to their reverse
transcriptase activity (Harmache et al., 1995).
Infectivity assays
Quantitation of HIV-1 infectivity was performed using
the C8166-CCR5/HIV-CAT indicator cell line (Fouchier et
al., 1997). A total of 5 3 105 cells were infected with viral
supernatants containing 104 cpm/ml of RT activity for 2 h
at 37°C. The medium was then replaced and cells were
incubated for 24 h. Whole cell lysates were prepared and
the levels of CAT activity measured using the CAT ELISA
(Roche). Parallel experiments were performed to deter-
mine the infectious titers (TCID50) of the same viral su-
pernatants. C8166-CCR5/HIV-CAT cells were seeded in
flat-bottom 96-well plates and infected with serial dilu-
tions of viral supernatants. Wells were scored for the
presence of syncitia at day 7 postinfection.MLV replication was monitored with the NIH 3T3 cell
line, using the same infection conditions as above. At
72 h postinfection, total cellular RNA was extracted as
previously described (Harmache et al., 1995). Serial
threefold dilutions were submitted to reverse transcrip-
tion using the One-Step RT-PCR system (Gibco-BRL),
with primers allowing the amplification of 559 bp corre-
sponding to a fragment of the spliced env viral RNA
(positions 651–670 and 6514–6495 for the forward and
reverse primers, respectively; Ott et al., 1992). As a con-
trol, a fragment of 382 bp of the GAPDH cellular RNA was
amplified using the previously described primers
CGAP1/CGAPR1 (Harmache et al., 1996). The amplified
products were analyzed by Southern blot hybridization
with 32P-labeled 4070A MLV env (positions 6445–6464,
Ott et al., 1992) and GAPDH (CGAP2, Harmache et al.,
1996) internal oligonucleotide probes, respectively.
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